Evidence shows that only a few newly developed diagnostic technologies to control and mitigate the recent health crisis- Covid-19 pandemic, have been successfully commercialized. Building on this, we review systematically the literature on the challenging and success factors of the commercialization of Covid-19 diagnostic technologies. In so doing, we draw on the six components of the Profiting From Innovation (PFI) framework, introduced by Teece (1986, 2006, 2018), including networking, supply chain, competitive manufacturing, services, appropriability regimes, and complementary technology, to provide major insights into technology commercialization challenges and success factors for Covid-19 diagnosis technologies. Also, the inductive approach is used to extract other challenges that were not addressed by the PFI framework. Our review makes significant theoretical contributions to innovation management (PFI framework) and crisis management research, and also draws policy implications. We also provide useful directions for future research.

有证据表明，只有少数新开发的用于控制和缓解最近的健康危机（Covid-19 大流行）的诊断技术已成功商业化。在此基础上，我们系统地回顾了有关 Covid-19 诊断技术商业化的挑战和成功因素的文献。在此过程中，我们利用 Teece（1986、2006、2018）提出的创新利润 (PFI) 框架的六个组成部分，包括网络、供应链、竞争性制造、服务、专有制度和补充技术，提供有关 Covid-19 诊断技术的技术商业化挑战和成功因素的重要见解。此外，归纳方法还用于提取 PFI 框架未解决的其他挑战。我们的综述对创新管理（PFI 框架）和危机管理研究做出了重大的理论贡献，并得出了政策启示。我们还为未来的研究提供了有用的方向。